Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2026-06-15 18:35:24 ET · period of report 2026-05-11 · accession 0001907345-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 18:35 | 2026-05-11 | LYEL | Lee Gary K. | CSO | S - Sale | $18.92 | -130 | 17.8K | -0.7% | -$2,460 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | S | D | 130 | $18.92 | 17,808 | D | — | — | (F1) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. (F2) The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. (F3) Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan. |